References
- Karshovska E, Weber C, Von Hundelshausen P. Platelet chemokines in health and disease. Thromb Haemost 2013;110(11):894–902. doi:https://doi.org/10.1160/TH13-04-0341.
- Yeaman MR. Platelets in defense against bacterial pathogens. Cell Mol Life Sci 2010;67(4):525–544. doi:https://doi.org/10.1007/s00018-009-0210-4.
- Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis 1997;25:951–968. doi:https://doi.org/10.1086/516120.
- Kraemer BF, Campbell RA, Schwertz H, Cody MJ, Franks Z, Tolley ND, Kahr WHA, Lindemann S, Seizer P, Yost CC, et al. Novel anti-bacterial activities of β-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathog 2011;7(11):e1002355. doi:https://doi.org/10.1371/journal.ppat.1002355.
- Hannachi N, Grac L, Baudoin JP, Fournier PE, Habib G, Camoin-Jau L. Effect of antiplatelet agents on platelet anti-staphylococcal capacity, in vitro study. Int J Antimicrob Agents 2020 Jan;7:105890. doi:https://doi.org/10.1016/j.ijantimicag.2020.105890.
- Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19(1):117–125. doi:https://doi.org/10.1111/j.1472-8206.2004.00299.x.
- Yang TF, Chu H, Ou SM, Li SY, Chen YT, Shih CJ, Tsai LW. Effect of statin therapy on mortality in patients with infective endocarditis. Am J Cardiol 2014;114(1):94–99. doi:https://doi.org/10.1016/j.amjcard.2014.03.064.
- Anavekar NS, Schultz JC, De Sa DDC, Thomas JM, Lahr BD, Tleyjeh IM, Steckelberg JM, Wilson WR, Baddour LM. Modifiers of symptomatic embolic risk in infective endocarditis. Mayo Clinic Proceedings 2011;86(11):1068–1074. doi:https://doi.org/10.4065/mcp.2011.0111.
- Caffrey AR, Timbrook TT, Noh E, Sakoulas G, Opal SM, Nizet V. Evidence to support continuation of statin therapy in patients with staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2017;23:61.
- López-Cortés LE, Gálvez-Acebal J, Del Toro MD, Velasco C, de Cueto M, Caballero FJ, Muniain MA, Pascual Á, Rodríguez-Baño J. Effect of statin therapy in the outcome of bloodstream infections due to Staphylococcus aureus: a prospective cohort study. PLoS ONE 2013;8(12):e82958. doi:https://doi.org/10.1371/journal.pone.0082958.
- Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, Howe B, Jones D, Joyce C, Kostner K, et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013;187(7):743–750. doi:https://doi.org/10.1164/rccm.201209-1718OC.
- Cattaneo M, Cerletti C, Harrison P, Hayward CPM, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost 2013;11(6):1183–1189. doi:https://doi.org/10.1111/jth.12231.
- Ciborowski M, Tomasiak M, Rusak T, Winnicka K, Dobrzycki S. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. Blood Coagul Fibrinolysis 2008;19(6):557–567. doi:https://doi.org/10.1097/MBC.0b013e3283079e29.
- Moraes LA, Vaiyapuri S, Sasikumar P, Ali MS, Kriek N, Sage T, Gibbins JM. Antithrombotic actions of statins involve PECAM-1 signaling. Blood 2013 Oct 31;122(18):3188–3196. doi:https://doi.org/10.1182/blood-2013-04-491845.
- Ali RA, Wuescher LM, Dona KR, Worth RG. Platelets mediate host-defense against S. aureus through direct bactericidal activity and by enhancing macrophage activities. J Immunol 2017;198(1):344–351. doi:https://doi.org/10.4049/jimmunol.1601178.
- Hannachi N, Habib G, Camoin Jau L. Aspirin effect on staphylococcus aureus-platelet interactions during infectious endocarditis. Front Med 2019;6. doi:https://doi.org/10.3389/fmed.2019.00217.
- Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002 12;105(6):739–745. doi:https://doi.org/10.1161/hc0602.103393.
- Masadeh M, Mhaidat N, Alzoubi K, Al-azzam S, Alnasser Z. Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann Clin Microbiol Antimicrob 2012;11(1):13. doi:https://doi.org/10.1186/1476-0711-11-13.
- Chow OA, von Kockritz-blickwede M, Bright AT, Hensler ME, Zinkernagel AS, Cogen AL, Gallo RL, Monestier M, Wang Y, Glass CK, et al. Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 2010;8(5):445–454. doi:https://doi.org/10.1016/j.chom.2010.10.005.
- Pawelczyk M, Chmielewski H, Kaczorowska B, Przybyła M, Baj Z. The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke. Arch Med Sci 2015 16;11(1):115–121. doi:https://doi.org/10.5114/aoms.2015.49216.
- Miajlovic H, Zapotoczna M, Geoghegan JA, Kerrigan SW, Speziale P, Foster TJ. Direct interaction of iron-regulated surface determinant IsdB of Staphylococcus aureus with the GPIIb/IIIa receptor on platelets. Microbiology 2010;156(Pt 3):920–928. doi:https://doi.org/10.1099/mic.0.036673-0.
- Liu C-Z, Huang T-F, Tsai P-J, Tsai P-J, Chang L-Y, Chang M-C. A segment of Staphylococcus aureus clumping factor A with fibrinogen-binding activity (ClfA221-550) inhibits platelet-plug formation in mice. Thromb Res 2007 28;121(2):183–191. doi:https://doi.org/10.1016/j.thromres.2007.03.019.
- Foster TJ. The remarkably multifunctional fibronectin binding proteins of Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 2016 23;35(12):1923–1931. doi:https://doi.org/10.1007/s10096-016-2763-0.
- Harrison P. Platelet Alpha-granular Fibrinogen. Platelets 1992;3(1):1–10. doi:https://doi.org/10.3109/09537109209013161.
- Wang K, Zuo G, Zheng L, Zhang C, Wang D, Cao Z, Hu S, Du X. Effects of tirofiban on platelet activation and endothelial function in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cell Biochem Biophys 2015;71(1):135–142. doi:https://doi.org/10.1007/s12013-014-0173-4.